Evidence map›Paper›PMID 40423778›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2025

Correction to: Safety and dosimetry of [

Mark N Gaze, Daria Handkiewicz-Junak, Raquel Hladun, Theodore W Laetsch, Caryn Sorge, Richard Sparks, Simon Wan, Antony Ceraulo, Aneta Kluczewska-Galka, Cristina Gámez-Cenzano and 9 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors.

Mark N GazeDepartment of Oncology, University College London Hospitals NHS Foundation Trust, London, UK.
Daria Handkiewicz-JunakMaria Skłodowska-Curie Memorial National Research Institute of Oncology, Gliwice, Poland.
Raquel HladunHospital Vall d'Hebrón, Barcelona, Spain.
Theodore W LaetschDivision of Oncology, Department of Pediatrics, Children's Hospital of Philadelphia, University of Pennsylvania, Philadelphia, PA, USA.
Caryn SorgeUniversity of Kentucky, Lexington, KY, USA.
Richard SparksCDE Dosimetry Services Inc, Knoxville, TN, USA.
Simon WanInstitute of Nuclear Medicine, University College London Hospitals NHS Foundation Trust, London, UK.
Antony CerauloPaediatric Oncology Department, Centre Léon Bérard, Lyon, France.
Aneta Kluczewska-GalkaMaria Skłodowska-Curie Memorial National Research Institute of Oncology, Gliwice, Poland.
Cristina Gámez-CenzanoVall d'Hebrón University Hospital, Barcelona, Spain.
Lisa J StatesDepartment of Radiology, Children's Hospital of Philadelphia, University of Pennsylvania, Philadelphia, PA, USA.
Riham El KhouliUniversity of Kentucky, Lexington, KY, USA.
Paola AimoneNovartis Pharma AG, Basel, Switzerland.
Kevin PerraudAdvanced Accelerator Applications International S.A., Geneva, Switzerland.
Gabor KollarAdvanced Accelerator Applications S.A., Ruel-Malmaison, France.
Fariba KhanshanNovartis Pharmaceuticals Corp, East Hanover, NJ, USA.
Lars BlumensteinNovartis Biomedical Research, Basel, Switzerland.
Fazia BrouriAdvanced Accelerator Applications International S.A., Geneva, Switzerland.
Anne-Laure GiraudetLumen Nuclear Medicine Department, Centre Léon Bérard, Lyon, France. annelaure.giraudet@lyon.unicancer.fr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID40423778
PMCPMC12589263

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.